Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
US11377503B2 · kind B2 · utility
3Cited by
30References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2019 |
| Grant date | Jul 5, 2022 |
| Priority date | — |
| Expiry date | Dec 3, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.